Greg Fulcher

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.5K citations · Full text

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey et al. · The Lancet Diabetes & Endocrinology · 2018 · 632 citations · Full text

Obesity, Metabolic Syndrome, Diabetes Management +12

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome

Russell Scott, Richard O’Brien, Greg Fulcher et al. · Diabetes Care · 2008 · 545 citations · Full text